Tivozanib
Brand names: Fotivda · Active ingredient: Tivozanib Hydrochloride
In short: FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
What is Tivozanib used for?
FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
Tivozanib dosage
The recommended dosage of FOTIVDA is 1.34 mg taken orally once daily for 21 days on treatment followed by 7 days off treatment for a 28-day cycle.
Continue treatment until disease progression or until unacceptable toxicity occurs.
Take FOTIVDA with or without food. Swallow the FOTIVDA capsule whole with a glass of water. Do not open the capsule.
If a dose is missed, the next dose should be taken at the next scheduled time. Do not take two doses at the same time.
Initiate medical management for diarrhea, nausea, or vomiting prior to dose interruption or reduction.
If dose modifications are required for adverse reactions, reduce the dosage of FOTIVDA to 0.89 mg for 21 days on treatment followed by 7 days off treatment for a 28-day cycle.
Recommendations for dosage modifications are provided in Table 1.
Adverse Reaction | SeverityGrades are based on the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). | Dosage Modifications for FOTIVDA
Hypertension
| Grade 3 | Withhold for Grade 3 that persists despite optimal anti-hypertensive therapy.
Resume at reduced dose when hypertension is controlled at less than or equal to Grade 2.
Grade 4 | Permanently discontinue.
Cardiac Failure
| Grade 3 | Withhold until improves to Grade 0 to 1 or baseline.
Resume at a reduced dose or discontinue depending on the severity and persistence of adverse reaction.
Grade 4 | Permanently discontinue.
Arterial Thromboembolic Events
| Any Grade | Permanently discontinue.
Hemorrhagic Events
| Grade 3 or 4 | Permanently discontinue.
Proteinuria
| 2 grams or greater proteinuria in 24 hours | Withhold until less than or equal to 2 grams of proteinuria per 24 hours.
Resume at a reduced dose.
Permanently discontinue for nephrotic syndrome.
Reversible Posterior Leukoencephalopathy Syndrome
| Any Grade | Permanently discontinue.
Other Adverse Reactions | Persistent or intolerable Grade 2 or 3 adverse reactionGrade 4 laboratory abnormality | Withhold until improves to Grade 0 to 1 or baseline.
Resume at reduced dose.
Grade 4 adverse reaction | Permanently discontinue.
Reduce the recommended dosage of FOTIVDA to 0.89 mg capsule taken orally once daily for 21 days on treatment followed by 7 days off treatment for a 28-day cycle for patients with moderate hepatic impairment .
How to take Tivozanib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling .
Hypertension and Hypertensive Crisis
Inform patients that hypertension or hypertensive crisis may occur during FOTIVDA treatment. Advise patients to undergo routine blood pressure monitoring and to contact their healthcare provider if blood pressure is elevated. Advise patients that if they experience signs or symptoms of hypertension to immediately contact their healthcare provider .
Cardiac Failure
Advise patients to immediately contact their healthcare provider if they develop symptoms of cardiac failure .
Cardiac Ischemia and Arterial Thromboembolic Events
Inform patients that arterial thromboembolic events (including fatal outcomes) may occur during FOTIVDA treatment. Advise patients to immediately contact their healthcare provider if new onset of chest discomfort, sudden weakness, or other events suggestive of a thrombotic event occurs .
Venous Thromboembolic Events
Advise patients to immediately contact their healthcare provider if they develop symptoms of dyspnea or localized limb edema . …
Warnings & precautions
Do not take this medicine if: None.
FOTIVDA can cause severe hypertension and hypertensive crisis. Hypertension occurred in 45% of patients treated with FOTIVDA, with 22% of the events > Grade 3. Median time to onset of hypertension was 2 weeks (range: 0 – 192 weeks).
Hypertensive crisis occurred in 0.8% of patients. One patient (0.1%) died due to hypertensive emergency after FOTIVDA overdose .
FOTIVDA has not been studied in patients with systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg.
Control blood pressure prior to treatment with FOTIVDA. Monitor blood pressure after 2 weeks and at least monthly thereafter during treatment with FOTIVDA. Treat patients with anti-hypertensive therapy when hypertension occurs during treatment with FOTIVDA.
Withhold FOTIVDA for severe hypertension despite optimal anti-hypertensive therapy. For persistent hypertension despite use of anti-hypertensive medications, reduce the FOTIVDA dose .
Discontinue FOTIVDA if hypertension is severe and persistent despite anti-hypertensive therapy and dose reduction of FOTIVDA, or in patients who experience hypertensive crisis.
If FOTIVDA is interrupted, monitor patients receiving anti-hypertensive medications for hypotension.
FOTIVDA can cause serious, sometimes fatal, cardiac failure. Cardiac failure in FOTIVDA-treated patients occurred in 1.6%, with 1% of events ≥ Grade 3, and 0.6% events were fatal.
FOTIVDA has not been studied in patients with symptomatic cardiac failure within the preceding 6 months before FOTIVDA treatment initiation.
Periodically monitor patients for symptoms of cardiac failure throughout treatment with FOTIVDA.
Management of cardiac failure events may require interruption, dose reduction, or permanent discontinuation of FOTIVDA therapy .
FOTIVDA can cause serious, sometimes fatal, cardiac ischemia and arterial thromboembolic events. …
Tivozanib side effects
The following clinically significant adverse reactions are also described elsewhere in the labeling:
Hypertension and Hypertensive Crisis
Cardiac Failure
Cardiac Ischemia and Arterial Thromboembolic Events
Venous Thromboembolic Events
Hemorrhagic Events
Proteinuria
Gastrointestinal Perforation and Fistula Formation
Thyroid Dysfunction
Risk of Impaired Wound Healing
Reversible Posterior Leukoencephalopathy Syndrome (RPLS)
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
The pooled safety population described in WARNINGS AND PRECAUTIONS reflects exposure to FOTIVDA administered at 1.34 mg orally once daily with or without food for 21 days on treatment followed by 7 days off treatment for a 28-day cycle in 1008 patients with advanced RCC in TIVO-3 and five other monotherapy studies. Among 1008 patients who received FOTIVDA, 52% were exposed for 6 months or longer and 34% were exposed for greater than one year.
Relapsed or Refractory Advanced RCC Following Two or More Prior Systemic Therapies
The safety of FOTIVDA was evaluated in TIVO-3, a randomized, open-label trial in 350 patients with relapsed or refractory advanced RCC who received 2 or 3 prior systemic treatments . …
Drug interactions
Strong CYP3A Inducers
Concomitant use of FOTIVDA with a strong CYP3A inducer decreases tivozanib exposure , which may reduce FOTIVDA anti-tumor activity.
Avoid concomitant use of strong CYP3A inducers with FOTIVDA.
About this medicine
Tivozanib is a kinase inhibitor. Tivozanib hydrochloride, the active ingredient, has the chemical name 1-{2-chloro-4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-3-(5-methylisoxazol-3-yl) urea hydrochloride hydrate. The molecular formula is C22H19ClN4O5 • HCl • H2O and the molecular weight is 509.34 Daltons. The chemical structure is:
Tivozanib hydrochloride is a white to light brown crystalline powder that is practically insoluble in water (0.09 mg/mL).
FOTIVDA 1.34 mg capsule contains 1.5 mg of tivozanib hydrochloride (equivalent to 1.34 mg tivozanib) with inactive ingredients: mannitol and magnesium stearate. Capsule composition: gelatin, titanium dioxide, FDA yellow iron oxide, and Blue SB-6018 (ink).
FOTIVDA 0.89 mg capsule contains 1.0 mg of tivozanib hydrochloride (equivalent to 0.89 mg tivozanib) with inactive ingredients: mannitol and magnesium stearate. Capsule composition: gelatin, titanium dioxide, FDA yellow iron oxide, FD&C Blue #2, Blue SB-6018 (ink) and Yellow SB-3017 (ink). The Yellow SB-3017 ink contains FD&C Yellow No.5 (tartrazine). …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID de77155c-ecf2-4f15-9758-21d271449d83. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate